InSite Vision Regains Development Rights for AzaSite Xtra™

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV) today announced that the company has regained North American development rights to azithromycin ophthalmic solution 2%, trademarked as AzaSite Xtra™, from Inspire Pharmaceuticals Inc., a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada. AzaSite Xtra, formulated in InSite’s DuraSite® topical drug delivery system, is a product candidate intended for the topical treatment of ocular infections.

Help employers find you! Check out all the jobs and post your resume.
MORE ON THIS TOPIC